Oloya, Jamaica P.
HRN: 21-96-64 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/20/2022
CO-AMOXICLAV 625MG (TAB)
10/20/2022
10/28/2022
PO
625mg
Bid
G1P1 (1001) PU Del Via Nsvd With RMLE, RAT Confirmed, COVID 19 Mild
Waiting Final Action
Indication: Prophylaxis Type of Infection: URTISkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes